e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia

Haematologica

Volumn 90, Issue 8, 2005, Pages 1139-1141

  Roti, Giovanni ^a   La Starza, Roberta ^a   Gorello, Paolo ^a   Gottardi, Enrico ^b   Crescenzi, Barbara ^a   Martelli, Massimo F ^a   Mecucci, Cristina ^a,c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c POLICLINICO MONTELUCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADULT; ARTICLE; BCR GENE; CASE REPORT; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; FUSION GENE; GENE; GENE DELETION; GENE MAPPING; GENOME ANALYSIS; HUMAN; MALE; MOLECULAR CLONING; MONITORING;

ADULT; ANTINEOPLASTIC AGENTS; DNA PRIMERS; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, CHRONIC; MALE; PIPERAZINES; PYRIMIDINES; SEQUENCE DELETION;

EID: 24944584680     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998;91:3357-65.
2. van Dongen JJ M, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease Report of the BIO-MED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-28.
3. Hayette S, Tigaud I, Thomas X, French M, Perrin MC, Nicolini F, et al. Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report. Leukemia 2004;18:1735-6.
4. Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N. e6a2 BCR-ABL trancripts in chronic myeloid leukemia: is it associated with aggressive diseased¿. Haematologica 2004;89:611-3.
5. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, et al. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukaemia. Blood 1996;88:2236-40.
6. Quentmeier H, Cools J, MacLeod RAF, Marynen P, Uphoff CC, Drexler HG. E6-a2 BCR/ABL1 fusion in T-cell acute lymphoblastic leukemia. Leukemia 2005;19:295-6.
7. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-84.
8. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003;102:2205-12.
9. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105:2281-6.